Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Arvinas
Biotech
Novartis pays $150M for Arvinas' prostate tumor protein degrader
The deal, which is worth up to $1.01 billion in milestones, will give Novartis global rights to a degrader of wild-type and mutant androgen receptor.
Nick Paul Taylor
Apr 11, 2024 8:04am
Bayer undergoes leadership shake-up—Chutes & Ladders
Mar 22, 2024 9:30am
Arvinas advances anti-resistance cancer drug on sign of efficacy
Jun 8, 2023 9:30am
Amarin CEO abruptly resigns—Chutes & Ladders
Apr 7, 2023 9:30am
Pfizer's $1B protein degradation bet yields 3% response rate
Nov 22, 2022 9:40am
Urica unites around new CEO Kranzler—Chutes & Ladders
Oct 7, 2022 9:56am